Cepheid (CPHD) Releases Quarterly Earnings Results
Cepheid (NASDAQ:CPHD) issued its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.09, Analyst Ratings Network.com reports. The company had revenue of $100.10 million for the quarter, compared to the consensus estimate of $93.70 million.
Several analysts have recently commented on the stock. Analysts at SunTrust initiated coverage on shares of Cepheid in a research note to investors on Thursday, October 10th. They set a “neutral” rating on the stock. On a related note, analysts at Wedbush raised their price target on shares of Cepheid from $37.00 to $42.00 in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Finally, analysts at Merrill Lynch downgraded shares of Cepheid from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. Cepheid currently has a consensus rating of “Hold” and an average price target of $40.53.
Cepheid (NASDAQ:CPHD) traded up 1.13% on Thursday, hitting $38.47. 597,031 shares of the company’s stock traded hands. Cepheid has a one year low of $28.12 and a one year high of $40.31. The stock’s 50-day moving average is $38.06 and its 200-day moving average is $36.54. The company’s market cap is $2.595 billion.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.